Pidotimod Market Overview
Pidomod (CAS 121808-62-6), also known as primo, spectrum Leyi, is an immunomodulator that can be used to prevent acute infection, shorten the course of the disease, reduce the severity of the disease, and can be used as an auxiliary drug during the acute infection period in patients with low immune function. Recurrent respiratory tract infections, urinary tract infections, and chronic bronchitis are the most common uses in children. It also has antiviral properties. Influenza and herpes virus are both effective. It's also effective against pneumococcal pneumonia, escherichia coli, pseudomonas aeruginosa, and Proteus infections.
In adults, pidotimod is effective in the prevention and treatment of acute infectious exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD). All these aforementioned aspects majorly contribute to the growth of the global Pidotimod market to a large extent.
| Report Metric | Details |
| Market size available for years | 2023–2030 |
| Base year considered | 2023 |
| Forecast period | 2024–2030 |
| Forecast unit | Value (USD Million) |
| Segments covered | Type, Application, and Region. |
| Regions covered | North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA) |
| Companies covered | Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical, Dr. Reddy’s. |
Covid-19 Impact on Pidotimod Market
In addition, the current Pidotimod Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Pidotimod Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Pidotimod Market Segment Overview
Based on the Application, Respiratory Infections is one of the largest segments of the global Pidotimod market. Respiratory tract infections (RTIs) are infections of parts of the body involved in breathing, such as the sinuses, throat, airways, or lungs. Moreover, Urinary Tract Infection (UTI) is another main segment in the market. A urinary tract infection (UTI) is an infection in any part of the urinary system such as kidneys, ureters, bladder, and urethra. Most infections involve the lower urinary tract — the bladder and the urethra.
Pidotimod Market, By Type
· Piece
· Oral Liquid
· Capsule
· Particles
· Other
Pidotimod Market, By Application
· Gynecological Infection
· Urinary Tract Infection (UTI)
· Respiratory Infections
· Other
Pidotimod Market Regional Overview
In terms of geography, the global Pidotimod market is classified into North America, Europe, Asia Pacific, South America, Middle East & Africa. North America is one of the most prominent regions for the global Pidotimod market. This is due to the increasing rate of various diseases and well- established healthcare sector. Moreover, the market in the Asia Pacific is expected to rise at a considerable rate in the forthcoming years. Important factors such as the large number of patients, growing healthcare sector, and development in the pharmaceutical industry are majorly contributing to the growth of the market in this region.
Pidotimod Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Pidotimod Market, Key Players
· Active Peptide Company
· Reco Tech
· Manus Aktteva Biopharma
· Joyochem
· Changzhou Yinsheng Pharmaceutical
· Dr. Reddy’s
Frequently Asked Questions (FAQ) :
Q1. What are the driving factors for the global Pidotimod market?
In adults, pidotimod is effective in the prevention and treatment of acute infectious exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD). This factor is expected to boost the growth of the global Pidotimod market.
Q2. Which Segments are covered in the global Pidotimod market report?
Type, Application, and Region. these segments are covered in the global Pidotimod market report.
Q3. Which segment is projected to hold the largest share in the global Pidotimod market?
Respiratory Infections segment is projected to hold the largest share in the global Pidotimod market.
Q4. Which region holds the largest share in the global Pidotimod market?
North America holds the largest share in the global Pidotimod market
Q5. Which are the prominent players in the global Pidotimod market?
Active Peptide Company, Reco Tech, Manus Aktteva Biopharma, Joyochem, Changzhou Yinsheng Pharmaceutical, Dr. Reddy’s. are some key players in the global Pidotimod market.
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Pidotimod Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type
- 5.2.1. Piece
- 5.2.2. Oral Liquid
- 5.2.3. Capsule
- 5.2.4. Particles
- 5.2.5. Other
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Gynecological Infection
- 5.3.2. Urinary Tract Infection (UTI)
- 5.3.3. Respiratory Infections
- 5.3.4. Other
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Pidotimod Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Type
- 6.2.1. Piece
- 6.2.2. Oral Liquid
- 6.2.3. Capsule
- 6.2.4. Particles
- 6.2.5. Other
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Gynecological Infection
- 6.3.2. Urinary Tract Infection (UTI)
- 6.3.3. Respiratory Infections
- 6.3.4. Other
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Pidotimod Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Type
- 7.2.1. Piece
- 7.2.2. Oral Liquid
- 7.2.3. Capsule
- 7.2.4. Particles
- 7.2.5. Other
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Gynecological Infection
- 7.3.2. Urinary Tract Infection (UTI)
- 7.3.3. Respiratory Infections
- 7.3.4. Other
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Pidotimod Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Type
- 8.2.1. Piece
- 8.2.2. Oral Liquid
- 8.2.3. Capsule
- 8.2.4. Particles
- 8.2.5. Other
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Gynecological Infection
- 8.3.2. Urinary Tract Infection (UTI)
- 8.3.3. Respiratory Infections
- 8.3.4. Other
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Pidotimod Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Type
- 9.2.1. Piece
- 9.2.2. Oral Liquid
- 9.2.3. Capsule
- 9.2.4. Particles
- 9.2.5. Other
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Gynecological Infection
- 9.3.2. Urinary Tract Infection (UTI)
- 9.3.3. Respiratory Infections
- 9.3.4. Other
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Active Peptide Company
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Reco Tech
- 10.6. Manus Aktteva Biopharma
- 10.7. Joyochem
- 10.8. Changzhou Yinsheng Pharmaceutical
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
